리스페리돈 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 투여 경로별, 용도별, 최종사용자별, 지역별 및 경쟁(2021-2031년)

The Global Risperidone Market is projected to expand from USD 6.36 Billion in 2025 to USD 8.58 Billion by 2031, reflecting a CAGR of 5.12%. As an atypical antipsychotic, risperidone is primarily employed in the management of schizophrenia, bipolar disorder, and autism-related irritability. Market stability is largely underpinned by increasing diagnostic rates for psychiatric conditions and the affordability of generic versions, which facilitates widespread access across healthcare systems worldwide. Additionally, the drug's proven effectiveness in stabilizing acute manic or psychotic episodes in both adult and pediatric patients ensures continuing demand.

However, market growth encounters a substantial hurdle regarding patient adherence, often compromised by adverse reactions such as weight gain and movement disorders. These safety concerns frequently lead prescribers to favor newer generation alternatives that offer improved tolerability. According to the International Federation of Pharmaceutical Manufacturers and Associations, mental health conditions impacted nearly one billion individuals globally in 2024. This extensive patient population underscores the urgent requirement for accessible treatments like risperidone, even amidst strong competitive pressure from novel therapeutic options.

Market Driver

The rising global prevalence of schizophrenia and bipolar disorder serves as a major engine for the Global Risperidone Market, requiring continuous pharmacological support to control chronic symptoms. As patient numbers grow, healthcare systems face increasing pressure to ensure the availability of antipsychotic therapies to alleviate the societal impact of severe psychiatric illnesses. Data from the Substance Abuse and Mental Health Services Administration in July 2025, referencing the '2024 National Survey on Drug Use and Health', indicates that approximately 14.6 million adults in the United States were identified as having a serious mental illness in 2024, highlighting the immense need for effective therapeutic solutions. This growing disease burden correlates directly with higher prescription rates for established antipsychotics such as risperidone.

Simultaneously, the market is evolving through the increased uptake of long-acting injectable formulations aimed at improving patient compliance and minimizing relapse rates linked to inconsistent oral dosing. Pharmaceutical developers are leveraging this shift by launching advanced delivery systems that provide extended-release benefits. For example, Teva Pharmaceutical Industries reported in its January 2025 'Fourth Quarter and Full Year 2024 Financial Results' that global revenue for UZEDY, its extended-release risperidone injectable, hit $117 million in 2024, exceeding initial expectations. This transition toward advanced formulations is also apparent in emerging markets; Luye Pharma Group noted in 2025 that revenue from its central nervous system portfolio, including the risperidone microsphere Rykindo, rose by 5.4% in the first half of the year.

Market Challenge

Expansion of the risperidone market is directly impeded by safety issues involving adverse effects, particularly weight gain and movement disorders. These physical reactions often lead to suboptimal patient compliance, forming a significant obstacle to sustained usage. When patients undergo considerable metabolic shifts or involuntary muscle contractions, they frequently stop treatment or demand adjustments to their medication plans. Consequently, healthcare providers are compelled to explore alternative therapies with better tolerability, thereby diminishing the reliance on and market share of established options like risperidone.

The trend toward newer generation antipsychotics is driven by the clinical necessity to manage symptoms consistently without causing debilitating side effects. The scale of this issue is highlighted by the widespread prevalence of conditions needing ongoing care; the World Health Organization reported in 2024 that schizophrenia affects roughly 24 million people worldwide, a large demographic for whom treatment continuity is vital but often disrupted by drug intolerance. As a result, the existence of safer pharmacological alternatives constrains risperidone's revenue potential, as physicians increasingly emphasize patient quality of life and adherence when making prescribing choices.

Market Trends

The creation of Once-Weekly Oral Gastric-Resident Capsules represents a significant technological breakthrough aimed at closing the gap between daily oral compliance and invasive injectable treatments. This innovation utilizes a novel dosage form that remains in the stomach to release medication steadily over a seven-day span, effectively reducing the pill burden that often hinders treatment success in schizophrenia patients. By sustaining stable plasma levels without requiring injections, this approach tackles adherence issues while respecting patient autonomy. According to the HMP Global Learning Network in June 2025, the article 'Novel Long-Acting Oral Formulation of Risperidone Shows Promise in Phase 3 Trial' reported that the investigational weekly capsule LYN-005 maintained therapeutic concentrations in the STARLYNG-1 study, reaching a geometric mean ratio for minimum concentration of 1.04 at week five relative to daily immediate-release risperidone.

Concurrently, the introduction of Generic Extended-Release Injectables is altering the competitive environment by offering affordable alternatives to long-established branded microsphere products. The approval and release of complex generic variants of standard long-acting antipsychotics are breaking the market exclusivity once enjoyed by originator drugs, leading to substantial price reductions and broader access for payers and patients. This transition compels branded manufacturers to focus on newer delivery technologies, while generics seize market share in the mature injectable sector. For instance, Lupin Limited announced in November 2025, within its 'Lupin Launches Generic Risperidone Extended-Release Injectable Suspension' report, that it had released its generic option in the United States, aiming for a total annual addressable market valued at roughly $187 million.

Key Market Players

• Otsuka Pharmaceutical Co., Ltd
• AbbVie Inc
• Dr. Reddy's Laboratories Ltd
• Pfizer Inc
• Endo International plc
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Viatris Inc
• Novartis AG
• Lupin Limited

Report Scope

In this report, the Global Risperidone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Risperidone Market, By Route Of Administration

• Injectable
• Oral
• Parenteral

Risperidone Market, By Application

• Schizophrenia
• Bipolar Disorder
• Irritability Associated with Autistic Disorder
• Others

Risperidone Market, By End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Risperidone Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Risperidone Market.

Available Customizations:

Global Risperidone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Risperidone Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Route Of Administration (Injectable, Oral, Parenteral)
  • 5.2.2. By Application (Schizophrenia, Bipolar Disorder, Irritability Associated with Autistic Disorder, Others)
  • 5.2.3. By End-Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Risperidone Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Route Of Administration
  • 6.2.2. By Application
  • 6.2.3. By End-Users
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Risperidone Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Route Of Administration
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End-Users
  • 6.3.2. Canada Risperidone Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Route Of Administration
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End-Users
  • 6.3.3. Mexico Risperidone Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Route Of Administration
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End-Users

7. Europe Risperidone Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Route Of Administration
  • 7.2.2. By Application
  • 7.2.3. By End-Users
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Risperidone Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Route Of Administration
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End-Users
  • 7.3.2. France Risperidone Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Route Of Administration
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End-Users
  • 7.3.3. United Kingdom Risperidone Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Route Of Administration
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End-Users
  • 7.3.4. Italy Risperidone Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Route Of Administration
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End-Users
  • 7.3.5. Spain Risperidone Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Route Of Administration
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End-Users

8. Asia Pacific Risperidone Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Route Of Administration
  • 8.2.2. By Application
  • 8.2.3. By End-Users
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Risperidone Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Route Of Administration
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End-Users
  • 8.3.2. India Risperidone Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Route Of Administration
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End-Users
  • 8.3.3. Japan Risperidone Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Route Of Administration
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End-Users
  • 8.3.4. South Korea Risperidone Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Route Of Administration
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End-Users
  • 8.3.5. Australia Risperidone Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Route Of Administration
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End-Users

9. Middle East & Africa Risperidone Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Route Of Administration
  • 9.2.2. By Application
  • 9.2.3. By End-Users
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Risperidone Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Route Of Administration
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End-Users
  • 9.3.2. UAE Risperidone Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Route Of Administration
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End-Users
  • 9.3.3. South Africa Risperidone Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Route Of Administration
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End-Users

10. South America Risperidone Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Route Of Administration
  • 10.2.2. By Application
  • 10.2.3. By End-Users
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Risperidone Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Route Of Administration
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End-Users
  • 10.3.2. Colombia Risperidone Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Route Of Administration
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End-Users
  • 10.3.3. Argentina Risperidone Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Route Of Administration
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End-Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Risperidone Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Otsuka Pharmaceutical Co., Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. AbbVie Inc
• 15.3. Dr. Reddy's Laboratories Ltd
• 15.4. Pfizer Inc
• 15.5. Endo International plc
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Sun Pharmaceutical Industries Ltd
• 15.8. Viatris Inc
• 15.9. Novartis AG
• 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer